By doing so, Semaglutide GLP-1 injections lower your A1C, reduce your risk of heart disease, and promote significant weight loss
Exenatide, another GLP-1 agonist, has been shown to have some impact on dopamine levels, but it is generally considered less effective for weight loss than semaglutide
25 The inhibition of these two proteins leads to a reduction in cholesterol levels, potentially benefiting the treatment of atherosclerotic conditions
Rybelsus delivers meaningful A1C reductions (around 1.5% on the 14 mg dose in PIONEER 1) and modest weight loss, but injectable semaglutide at higher doses produces larger effects
Study Protocol The study is a single-center, double-blind, randomized, placebo-controlled 4-arm study design